Interleukin-6 is an autocrine growth factor in human prostate cancer
Interleukin-6 is an autocrine growth factor in human prostate cancer
复制标题
DOI：
10.1016/s0002-9440(10)63067-2
复制
发表时间：
2001-12-01
影响因子：
6
通讯作者：
Ittmann, M
中科院分区：
文献类型：
--
作者：
Giri, D;Ozen, M;Ittmann, M
前列腺癌是美国男性中最常见的癌症，也是该群体癌症死亡的第二大原因。我们已经发现，与正常前列腺组织相比，在临床上局限的前列腺癌中，白细胞介素（IL）-6蛋白浓度增加了18倍。除了LNCaP细胞之外，培养物中的正常和肿瘤前列腺上皮细胞分泌IL-6。向培养物中的原代上皮细胞或LNCaP前列腺癌细胞系添加外源性IL-6导致Stat-3的磷酸化和净细胞增殖的增加。通过免疫组织化学方法，前列腺癌组织中IL-6受体的浓度增加了八倍，并且在癌细胞中也增加了。通过Ki 67免疫组织化学评估，IL-6受体表达的增加与体内前列腺癌细胞增殖的增加相关。这些发现有力地支持了IL-6在原发性雄激素依赖性前列腺癌中作为体内重要的自分泌生长因子的假设。
Prostate cancer is the most common cancer in American men and the second leading cause of cancer deaths in this group. We have found that interleukin (IL)-6 protein concentrations are increased similar to 18-fold in clinically localized prostate cancers when compared to normal prostate tissue. Normal and neoplastic prostatic epithelial cells in culture, with the exception of LNCaP cells, secrete IL-6. Addition of exogenous IL-6 to primary epithelial cells in culture or the LNCaP prostate cancer cell line leads to phosphorylation of Stat-3 and increases in net cell proliferation. The concentration of IL-6 receptor is increased eightfold in the prostate cancer tissues and is increased in the cancer cells by immunohistochemistry. The increased expression of IL-6 receptor is correlated with increased proliferation of prostate cancer cells in vivo as assessed by Ki67 immunohistochemistry. These findings strongly support the hypothesis that IL-6 acts as a significant autocrine growth factor in vivo for primary, androgen-dependent prostate cancers.